

Jacques Izopet

List of PR Articles by Year in descending order

Source: [//exaly.com/author-pdf/6444997/publications.pdf](https://exaly.com/author-pdf/6444997/publications.pdf)

Version: 2025-02-01

293

PR articles

15,833

PR citations

8087

66

PR h-index

10747

123

g-index

328

documents

19981

doc citations

8682

71

h-index

15039

citing authors

#	ARTICLE	IF	PR CITATIONS
1	Characterization of virus-host recombinant variants of the hepatitis E virus. <i>Journal of Virology</i> , 2024, 98, .	3.7	7
2	Low serum neutralization of Omicron variants a month after AZD7442 prophylaxis initiation. <i>Journal of Infection</i> , 2023, 86, 66-117.	2.9	9
3	Low to undetectable Omicron BQ.1.1 neutralization by patient's sera a month after initiation of AZD7442 600mg. <i>Journal of Infection</i> , 2023, 86, e126-e129.	2.9	7
4	Clustered Cases of Waterborne Hepatitis E Virus Infection, France. <i>Viruses</i> , 2023, 15, 1149.	3.3	14
5	SARS-CoV-2 Co-Infections and Recombinations Identified by Long-Read Single-Molecule Real-Time Sequencing. <i>Microbiology Spectrum</i> , 2023, 11, .	3.7	10
6	Molecular evolution of omicron variant in immunocompromised individuals with chronic SARS-CoV-2 infection. <i>Journal of Infection</i> , 2023, 87, e89-e93.	2.9	2
7	Efficiency of a boost with a third dose of anti-SARS-CoV-2 messenger RNA-based vaccines in solid organ transplant recipients. <i>American Journal of Transplantation</i> , 2022, 22, 322-323.	4.6	124
8	Heterologous ChAdOx1-S/BNT162b2 Vaccination: Neutralizing Antibody Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). <i>Clinical Infectious Diseases</i> , 2022, 74, 1315-1316.	5.4	14
9	Antibody titers and protection against a SARS-CoV-2 infection. <i>Journal of Infection</i> , 2022, 84, 248-288.	2.9	107
10	Influence of treatment with neutralizing monoclonal antibodies on the SARS-CoV-2 nasopharyngeal load and quasispecies. <i>Clinical Microbiology and Infection</i> , 2022, 28, 139.e5-139.e8.	5.5	30
11	Post-Vaccination Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Kinetics and Protection Duration. <i>Clinical Infectious Diseases</i> , 2022, 75, e924-e925.	5.4	14
12	Vectorial Release of Human RNA Viruses from Epithelial Cells. <i>Viruses</i> , 2022, 14, 231.	3.3	3
13	Antibody titers and breakthrough infections with Omicron SARS-CoV-2. <i>Journal of Infection</i> , 2022, 84, e13-e15.	2.9	33
14	Influence of the Delta Variant and Vaccination on the SARS-CoV-2 Viral Load. <i>Viruses</i> , 2022, 14, 323.	3.3	14
15	Impact of Casirivimab-Imdevimab on Severe Acute Respiratory Syndrome Coronavirus 2 Delta Variant Nasopharyngeal Virus Load and Spike Quasispecies. <i>Open Forum Infectious Diseases</i> , 2022, 9, .	0.8	7
16	Humoral and Cellular Immune Responses of Solid Organ Transplant Patients on Belatacept to Three Doses of mRNA-Based Anti-SARS-CoV-2 Vaccine. <i>Vaccines</i> , 2022, 10, 354.	3.0	10
17	Influence of vaccination and prior immunity on the dynamics of Omicron BA.1 and BA.2 sub-variants. <i>Journal of Infection</i> , 2022, 84, 834-872.	2.9	6
18	Novel T cell interferon gamma release assay (IGRA) using spike recombinant protein for COVID19 vaccine response and Nucleocapsid for SARS-Cov2 response. <i>Clinical Immunology</i> , 2022, 237, 108979.	2.8	18

#	ARTICLE	IF	PR CITATIONS
19	Predictive Factors for Humoral Response After 2-dose SARS-CoV-2 Vaccine in Solid Organ Transplant Patients. <i>Transplantation Direct</i> , 2022, 8, e1248.	1.7	28
20	Comparative effects of mRNA vaccine booster and natural Omicron infection on the neutralizing antibody response. <i>Journal of Infection</i> , 2022, 85, e4-e6.	2.9	6
21	Persistence of hepatitis E virus in the cerebrospinal fluid despite apparently successful ribavirin therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2022, 77, 2300-2303.	3.2	5
22	Diagnostic Performance of an Automated System for Assaying Anti-Hepatitis E Virus Immunoglobulins M and G Compared with a Conventional Microplate Assay. <i>Viruses</i> , 2022, 14, 1065.	3.3	10
23	Decreased Efficiency of Neutralizing Antibodies from Previously Infected or Vaccinated Individuals against the B.1.617.2 (Delta) SARS-CoV-2 Variant. <i>Microbiology Spectrum</i> , 2022, 10, .	3.7	7
24	Can the COVID-19 Pandemic Improve the Management of Solid Organ Transplant Recipients?. <i>Viruses</i> , 2022, 14, 1860.	3.3	1
25	Human Cytomegalovirus Modifies Placental Small Extracellular Vesicle Composition to Enhance Infection of Fetal Neural Cells In Vitro. <i>Viruses</i> , 2022, 14, 2030.	3.3	8
26	Post-vaccination SARS-CoV-2 antibody kinetics and protection duration against Omicron in elderly population. <i>Journal of Infection</i> , 2022, 85, 702-769.	2.9	7
27	Antibody Titers and Protection against Omicron (BA.1 and BA.2) SARS-CoV-2 Infection. <i>Vaccines</i> , 2022, 10, 1548.	3.0	40
28	Omicron Wave SARS-CoV-2 Diagnosis: Evaluation of Saliva, Anterior Nasal, and Nasopharyngeal Swab Samples. <i>Microbiology Spectrum</i> , 2022, 10, .	3.7	15
29	Antiviral and Anti-Inflammatory Activities of Fluoxetine in a SARS-CoV-2 Infection Mouse Model. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13623.	4.5	21
30	Quantifying the impact of public health protection measures on the spread of SARS-CoV-2. <i>Journal of Infection</i> , 2021, 82, 414-451.	2.9	5
31	Screening for SARS-CoV-2 antibodies among healthcare workers in a university hospital in southern France. <i>Journal of Infection</i> , 2021, 82, e29-e32.	2.9	15
32	Determining the therapeutic range for ribavirin in transplant recipients with chronic hepatitis E virus infection. <i>Journal of Viral Hepatitis</i> , 2021, 28, 431-435.	2.1	8
33	Classification of the Zoonotic Hepatitis E Virus Genotype 3 Into Distinct Subgenotypes. <i>Frontiers in Microbiology</i> , 2021, 11, .	3.9	44
34	An Evaluation of Hepatitis E Virus Molecular Typing Methods. <i>Clinical Chemistry</i> , 2021, 68, 181-191.	1.1	10
35	Effector memory CD8 T cell response elicits Hepatitis E Virus genotype 3 pathogenesis in the elderly. <i>PLoS Pathogens</i> , 2021, 17, e1009367.	4.4	25
36	Estimating the impact of public health strategies on the spread of SARS-CoV-2: Epidemiological modelling for Toulouse, France. <i>Reviews in Medical Virology</i> , 2021, 31, 1-8.	7.0	7

#	ARTICLE	IF	PR CITATIONS
37	Mechanisms of HIV-1 evasion to the antiviral activity of chemokine CXCL12 indicate potential links with pathogenesis. <i>PLoS Pathogens</i> , 2021, 17, e1009526.	4.4	15
38	RÃ©plication du virus de lâ€™hÃ©patite E dans les cellules intestinales. <i>Medecine/Sciences</i> , 2021, 37, 320-322.	0.2	0
39	Analyses of Clinical and Biological Data for French and Belgian Immunocompetent Patients Infected With Hepatitis E Virus Genotypes 4 and 3. <i>Frontiers in Microbiology</i> , 2021, 12, .	3.9	9
40	Influence of SARS-CoV-2 Variant B.1.1.7, Vaccination, and Public Health Measures on the Spread of SARS-CoV-2. <i>Viruses</i> , 2021, 13, 898.	3.3	7
41	Side effect of a 6 p.m curfew for preventing the spread of SARS-CoV-2: A modeling study from Toulouse, France. <i>Journal of Infection</i> , 2021, 82, 186-230.	2.9	9
42	Influence of age on the spread of SARS-CoV-2 variant B.1.1.7. <i>Journal of Clinical Virology</i> , 2021, 141, 104872.	3.1	4
43	Hepatitis A: Epidemiology, High-Risk Groups, Prevention and Research on Antiviral Treatment. <i>Viruses</i> , 2021, 13, 1900.	3.3	138
44	Rat Hepatitis E Virus: Presence in Humans in South-Western France?. <i>Frontiers in Medicine</i> , 2021, 8, .	2.6	18
45	One year later: SARS-CoV-2 immune response and vaccination of healthcare workers post-infection. <i>Journal of Infection</i> , 2021, 83, 381-412.	2.9	7
46	Adaptive lymphocyte profile analysis discriminates mild and severe forms of COVID-19 after solid organ transplantation. <i>Kidney International</i> , 2021, 100, 915-927.	5.0	7
47	Mobilization of Î³Î³ T Cells and IL-10 Production at the Acute Phase of Hepatitis E Virus Infection in Cytomegalovirus Carriers. <i>Journal of Immunology</i> , 2021, 206, 1027-1038.	0.6	9
48	Hepatitis E Virus Quasispecies in Cerebrospinal Fluid with Neurological Manifestations. <i>Vaccines</i> , 2021, 9, 1205.	3.0	17
49	Assessment of 4 Doses of SARS-CoV-2 Messenger RNAâ€™Based Vaccine in Recipients of a Solid Organ Transplant. <i>JAMA Network Open</i> , 2021, 4, e2136030.	6.8	113
50	Evaluation of Three Quantitative Anti-SARS-CoV-2 Antibody Immunoassays. <i>Microbiology Spectrum</i> , 2021, 9, .	3.7	24
51	Prediction of SARS-CoV-2 Variant Lineages Using the S1-Encoding Region Sequence Obtained by PacBio Single-Molecule Real-Time Sequencing. <i>Viruses</i> , 2021, 13, 2544.	3.3	13
52	Hepatitis E Virus Infection: Neurological Manifestations and Pathophysiology. <i>Pathogens</i> , 2021, 10, 1582.	3.1	25
53	THETA: a new genotypic approach for predicting HIV-1 CRF02_AG coreceptor usage. <i>Bioinformatics</i> , 2020, 36, 416-421.	4.8	4
54	Hepatitis E virus replication in human intestinal cells. <i>Gut</i> , 2020, 69, 901-910.	21.2	88

#	ARTICLE	IF	PR CITATIONS
55	Performance of the Xpert HBV Viral Load assay versus the Aptima Quant assay for quantifying hepatitis B virus DNA. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020, 96, 114946.	1.7	30
56	Ribavirin for Hepatitis E Virus Infection After Organ Transplantation: A Large European Retrospective Multicenter Study. <i>Clinical Infectious Diseases</i> , 2020, 71, 1204-1211.	5.4	100
57	Performance evaluation of the Vela Dx Sentosa next-generation sequencing system for HIV-1 DNA genotypic resistance. <i>Journal of Clinical Virology</i> , 2020, 122, 104229.	3.1	21
58	Risk for Hepatitis E Virus Transmission by Solvent/Detergent-Treated Plasma. <i>Emerging Infectious Diseases</i> , 2020, 26, 2881-2886.	3.9	14
59	Addition of Maraviroc Versus Placebo to Standard Antiretroviral Therapy for Initial Treatment of Advanced HIV Infection. <i>Annals of Internal Medicine</i> , 2020, 172, 297.	10.4	10
60	Hepatitis E Virus: How It Escapes Host Innate Immunity. <i>Vaccines</i> , 2020, 8, 422.	3.0	20
61	No evidence of sexual transmission of HEV among individuals using HIV pre-exposure prophylaxis. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1495-1501.	2.1	15
62	Evaluation of the Aptima [®] transcription-mediated amplification assay (Hologic [®]) for detecting SARS-CoV-2 in clinical specimens. <i>Journal of Clinical Virology</i> , 2020, 129, 104541.	3.1	36
63	Insertions and Duplications in the Polyproline Region of the Hepatitis E Virus. <i>Frontiers in Microbiology</i> , 2020, 11, .	3.9	658
64	Clinical Manifestations, Pathogenesis and Treatment of Hepatitis E Virus Infections. <i>Journal of Clinical Medicine</i> , 2020, 9, 331.	2.6	111
65	Optimized Hepatitis E Virus (HEV) Culture and Its Application to Measurements of HEV Infectivity. <i>Viruses</i> , 2020, 12, 139.	3.3	28
66	The SARS-CoV-2 seroprevalence is the key factor for deconfinement in France. <i>Journal of Infection</i> , 2020, 81, 318-356.	2.9	23
67	Update: proposed reference sequences for subtypes of hepatitis E virus (species Orthohepevirus A). <i>Journal of General Virology</i> , 2020, 101, 692-698.	3.3	330
68	Seroprevalence of hepatitis E virus among blood donors on Corsica, France, 2017. <i>Eurosurveillance</i> , 2020, 25, .	5.0	13
69	Plasma Hepatitis E Virus Kinetics in Solid Organ Transplant Patients Receiving Ribavirin. <i>Viruses</i> , 2019, 11, 630.	3.3	10
70	Hepatitis E virus infections in Europe. <i>Journal of Clinical Virology</i> , 2019, 120, 20-26.	3.1	71
71	Failure to respond to ribavirin despite elevated intraerythrocyte zinc level in transplant patients with chronic hepatitis E virus infection. <i>Transplant Infectious Disease</i> , 2019, 21, .	2.2	9
72	Performance characteristics of the VIDAS [®] ANTI-HEV IgM and IgG assays. <i>Journal of Clinical Virology</i> , 2019, 112, 10-14.	3.1	17

#	ARTICLE	IF	PR CITATIONS
73	Multirecombinant Enterovirus A71 Subgenogroup C1 Isolates Associated with Neurologic Disease, France, 2016–2017. <i>Emerging Infectious Diseases</i> , 2019, 25, 1204-1208.	3.9	25
74	Transfusion-Transmitted Hepatitis E Virus Infection in France. <i>Transfusion Medicine Reviews</i> , 2019, 33, 146-153.	1.6	62
75	Hepatitis E Virus Infections among Patients with Acute Febrile Jaundice in Burkina Faso. <i>Viruses</i> , 2019, 11, 554.	3.3	12
76	Viral load and clinical manifestations of hepatitis E virus genotype 3 infections. <i>Journal of Viral Hepatitis</i> , 2019, 26, 1139-1142.	2.1	15
77	Screening, diagnosis and risks associated with Hepatitis E virus infection. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 403-418.	4.0	27
78	Hepatitis E Virus (HEV) Open Reading Frame 2 Antigen Kinetics in Human-Liver Chimeric Mice and Its Impact on HEV Diagnosis. <i>Journal of Infectious Diseases</i> , 2019, 220, 811-819.	3.8	22
79	Peripheral Plasma and Semen Cytokine Response to Zika Virus in Humans. <i>Emerging Infectious Diseases</i> , 2019, 25, 823-825.	3.9	12
80	Should 12- or 24-week post-ribavirin follow-up be considered to define sustained virological response in transplant patients treated for chronic hepatitis E virus infection?. <i>Transplant Infectious Disease</i> , 2019, 21, .	2.2	4
81	No evidence of occult hepatitis C or E virus infections in liver-transplant patients with sustained virological response after therapy with direct acting agents. <i>Transplant Infectious Disease</i> , 2019, 21, .	2.2	5
82	The Prevalence of Hepatitis E in a Patient Cohort Presenting With Addictive Injection Behavior. <i>Frontiers in Psychiatry</i> , 2019, 10, .	2.6	4
83	Long-term evolution of transmitted CXCR4-using HIV-1 under effective antiretroviral therapy. <i>Aids</i> , 2019, 33, 1977-1985.	2.5	2
84	Impact of the mutational load on the virological response to a first-line rilpivirine-based regimen. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 718-721.	3.2	4
85	Vectorial Release of Hepatitis E Virus in Polarized Human Hepatocytes. <i>Journal of Virology</i> , 2019, 93, .	3.7	50
86	Hepatitis E virus genotype 3 and capsid protein in the blood and urine of immunocompromised patients. <i>Journal of Infection</i> , 2019, 78, 232-240.	2.9	41
87	Monitoring hepatitis E virus fecal shedding to optimize ribavirin treatment duration in chronically infected transplant patients. <i>Journal of Hepatology</i> , 2019, 70, 206-209.	3.6	32
88	Baseline and Post-Treatment Hepatitis C NS5A Resistance in Relapsed Patients from a Multicentric Real-Life Cohort. <i>Antiviral Therapy</i> , 2018, 23, 307-314.	2.1	4
89	Four-days-a-week antiretroviral maintenance therapy in virologically controlled HIV-1-infected adults: the ANRS 162-4D trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 738-747.	3.2	30
90	HIV-1 genotypic resistance testing using the Vela automated next-generation sequencing platform. <i>Journal of Antimicrobial Chemotherapy</i> , 2018, 73, 1152-1157.	3.2	30

#	ARTICLE	IF	PR CITATIONS
91	A European multicenter study on the analytical performance of the VERIS HBV assay. <i>Journal of Clinical Virology</i> , 2018, 99-100, 50-56.	3.1	2
92	Transmission of Hepatitis E Virus With Plasma Exchange in Kidney Transplant Recipients. <i>Transplantation</i> , 2018, 102, 1351-1357.	1.2	17
93	Transmission and Epidemiology of Hepatitis E Virus Genotype 3 and 4 Infections. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2018, 8, a032144.	6.7	88
94	Hepatitis E Virus Lifecycle and Identification of 3 Forms of the ORF2 Capsid Protein. <i>Gastroenterology</i> , 2018, 154, 211-223.e8.	1.0	190
95	Retreatment with direct-acting antivirals of genotypes 1-3-4 hepatitis C patients who failed an anti-NS5A regimen in real world. <i>Journal of Hepatology</i> , 2018, 68, 595-597.	3.6	9
96	Kinetics of anti-ZIKV antibodies after Zika infection using two commercial enzyme-linked immunoassays. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 90, 26-30.	1.7	44
97	Should Persistent Hepatitis E Virus Replication in Transplant Patients Be Tolerated?. <i>Transplantation</i> , 2018, 102, e84-e85.	1.2	1
98	Monitoring human enteric viruses in wastewater and relevance to infections encountered in the clinical setting: a one-year experiment in central France, 2014 to 2015. <i>Eurosurveillance</i> , 2018, 23, .	5.0	144
99	Genotype specific pathogenicity of hepatitis E virus at the human maternal-fetal interface. <i>Nature Communications</i> , 2018, 9, .	13.9	115
100	Hepatitis E prevalence in French Polynesian blood donors. <i>PLoS ONE</i> , 2018, 13, e0208934.	2.4	9
101	CCR5 structural plasticity shapes HIV-1 phenotypic properties. <i>PLoS Pathogens</i> , 2018, 14, e1007432.	4.4	32
102	Performance of a commercial assay for detecting and quantifying HEV RNA in faeces. <i>Journal of Clinical Virology</i> , 2018, 109, 1-5.	3.1	7
103	Accurate quantification of CXCR4-using HIV-1 variants by Illumina deep-sequencing. <i>Aids</i> , 2018, 32, 2429-2431.	2.5	1
104	Hepatitis E virus-associated cryoglobulinemia in solid organ transplant recipients. <i>Liver International</i> , 2018, 38, 2178-2189.	4.1	33
105	Impact of donor BK polyomavirus replication on recipient infections in living donor transplantation. <i>Transplant Infectious Disease</i> , 2018, 20, .	2.2	20
106	Ultrasensitive Human Immunodeficiency Virus Type 1 Viral Load as a Marker of Treatment Choice for Simplification Strategies. <i>Clinical Infectious Diseases</i> , 2018, 67, 1883-1889.	5.4	5
107	Diversity of hepatitis E virus genotype 3. <i>Reviews in Medical Virology</i> , 2018, 28, .	7.0	43
108	Detection of Zika, dengue and chikungunya viruses using single-reaction multiplex real-time RT-PCR. <i>Diagnostic Microbiology and Infectious Disease</i> , 2018, 92, 284-287.	1.7	29

#	ARTICLE	IF	PR CITATIONS
109	A fully automated system using transcription-mediated amplification for the molecular diagnosis of hepatitis E virus in human blood and faeces. <i>Journal of Clinical Virology</i> , 2018, 105, 109-111.	3.1	8
110	Acute hepatitis E in French patients and neurological manifestations. <i>Journal of Infection</i> , 2018, 77, 220-226.	2.9	64
111	Impact of Human Immunodeficiency Virus Type 1 Minority Variants on the Virus Response to a Rilpivirine-Based First-line Regimen. <i>Clinical Infectious Diseases</i> , 2018, 66, 1588-1594.	5.4	20
112	Performance comparison of deep sequencing platforms for detecting HIV-1 variants in the pol gene. <i>Journal of Medical Virology</i> , 2018, 90, 1486-1492.	3.8	8
113	Performance comparison of next-generation sequencing platforms for determining HIV-1 coreceptor use. <i>Scientific Reports</i> , 2017, 7, .	3.5	11
114	A European multicentre study on the comparison of HCV viral loads between VERIS HCV assay and COBAS Â® TaqMan Â® HCV Test and RealTime HCV Assay. <i>Journal of Clinical Virology</i> , 2017, 90, 18-25.	3.1	5
115	Transmission of hepatitis E virus infection to human-liver chimeric FRG mice using patient plasma. <i>Antiviral Research</i> , 2017, 141, 150-154.	3.8	53
116	Evaluation of two VIDAS Â® prototypes for detecting anti-HEV IgG. <i>Journal of Clinical Virology</i> , 2017, 89, 46-50.	3.1	9
117	Study of hepatitis E virus infection of genotype 1 and 3 in mice with humanised liver. <i>Gut</i> , 2017, 66, 920-929.	21.2	126
118	European Multicenter Study on Analytical Performance of DxN Veris System HCV Assay. <i>Journal of Clinical Microbiology</i> , 2017, 55, 1186-1192.	4.1	6
119	Characterization of the lipid envelope of exosome encapsulated HEV particles protected from the immune response. <i>Biochimie</i> , 2017, 141, 70-79.	2.9	119
120	Malignancies in hepatitis C virus-â€positive and -â€negative kidney transplant recipients: A case-â€controlled study. <i>Transplant Infectious Disease</i> , 2017, 19, .	2.2	3
121	A European multicentre study on the comparison of HIV-1 viral loads between VERIS HIV-1 Assay and Roche COBASÂ® TAQMANÂ® HIV-1 test, Abbott RealTime HIV-1 Assay, and Siemens VERSANT HIV-1 Assay. <i>Journal of Clinical Virology</i> , 2017, 92, 75-82.	3.1	8
122	HEV infection in French HIV-infected patients. <i>Journal of Infection</i> , 2017, 74, 310-313.	2.9	31
123	Chronic hepatitis E virus infection in a cirrhotic patient. <i>Medicine (United States)</i> , 2017, 96, e7915.	1.3	19
124	Transfusion-â€acquired hepatitis E infection misdiagnosed as severe critical illness polyneuromyopathy in a heart transplant patient. <i>Transplant Infectious Disease</i> , 2017, 19, .	2.2	15
125	A European multicentre study on the comparison of HBV viral loads between VERIS HBV assay and Roche COBAS Â® TAQMAN Â® HBV test, Abbott RealTime HBV assay, Siemens VERSANT HBV assay, and Qiagen artus HBV RG kit. <i>Journal of Clinical Virology</i> , 2017, 95, 76-83.	3.1	13
126	Hepatitis E virus infection and acute non-traumatic neurological injury: A prospective multicentre study. <i>Journal of Hepatology</i> , 2017, 67, 925-932.	3.6	91

#	ARTICLE	IF	PR CITATIONS
127	Atypical hemolytic uremic syndrome triggered by varicella infection. IDCases, 2017, 9, 89-90.	0.8	7
128	Clinical phenotype and outcome of hepatitis E virus-associated neuralgic amyotrophy. Neurology, 2017, 89, 909-917.	1.0	88
129	Hepatitis E virus infection. Nature Reviews Disease Primers, 2017, 3, .	50.7	521
130	HEV and transfusion-recipient risk. Transfusion Clinique Et Biologique, 2017, 24, 176-181.	0.2	43
131	European Multicenter Study on Analytical Performance of Veris HIV-1 Assay. Journal of Clinical Microbiology, 2017, 55, 2055-2063.	4.1	2
132	Is the unbound concentration of atazanavir of interest in therapeutic drug monitoring?. Fundamental and Clinical Pharmacology, 2017, 31, 245-253.	2.5	3
133	Comparison of Cobas® HPV and Anyplex®,c II HPV28 assays for detecting and genotyping human papillomavirus. Diagnostic Microbiology and Infectious Disease, 2017, 87, 25-27.	1.7	9
134	Hepatitis E Virus Infection in Solid Organ Transplant Recipients, France. Emerging Infectious Diseases, 2017, 23, 353-356.	3.9	29
135	Rabbit Hepatitis E Virus Infections in Humans, France. Emerging Infectious Diseases, 2017, 23, 1191-1193.	3.9	164
136	Patterns of residual HIV-1 RNA shedding in the seminal plasma of patients on effective antiretroviral therapy. Basic and Clinical Andrology, 2017, 27, .	1.7	13
137	Zika Virus Infection and Prolonged Viremia in Whole-Blood Specimens. Emerging Infectious Diseases, 2017, 23, 863-865.	3.9	89
138	Natural non-homologous recombination led to the emergence of a duplicated V3-NS5A region in HCV-1b strains associated with hepatocellular carcinoma. PLoS ONE, 2017, 12, e0174651.	2.4	2
139	L'hepatite E, une infection virale encore méconnue dans les pays industriels. Bulletin De L'Academie Nationale De Medecine, 2017, 201, 641-648.	0.1	0
140	Treatment of HEV Infection in Patients with a Solid-Organ Transplant and Chronic Hepatitis. Viruses, 2016, 8, 222.	3.3	42
141	Persistent But Not Replicating HIV-1 Cell-Associated DNA in Semen of Long-Term ART Experienced Men. Current HIV Research, 2016, 14, 316-323.	0.8	1
142	Hepatitis E Pathogenesis. Viruses, 2016, 8, 212.	3.3	91
143	Quantification of HEV RNA by Droplet Digital PCR. Viruses, 2016, 8, 233.	3.3	31
144	A Follow-Up of the Multicenter Collaborative Study on HIV-1 Drug Resistance and Tropism Testing Using 454 Ultra Deep Pyrosequencing. PLoS ONE, 2016, 11, e0146687.	2.4	15

#	ARTICLE	IF	PR CITATIONS
145	Brief Report: HIV-1 Tropism During Primary Infections in France: 1996–2014. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2016, 72, 376-379.	1.8	5
146	Extrahepatic manifestations of hepatitis E virus. <i>Liver International</i> , 2016, 36, 467-472.	4.1	110
147	Treatment of autochthonous acute hepatitis E with short-term ribavirin: a multicenter retrospective study. <i>Liver International</i> , 2016, 36, 328-333.	4.1	68
148	A 3-month course of ciprofloxacin does not prevent BK virus replication in heavily immunosuppressed kidney-transplant patients. <i>Journal of Clinical Virology</i> , 2016, 79, 61-67.	3.1	17
149	Detection of Hepatitis E Virus in Sewage After an Outbreak on a French Island. <i>Food and Environmental Virology</i> , 2016, 8, 194-199.	2.6	60
150	Analytical performance of the VERIS MDx system HCV assay for detecting and quantifying HCV RNA. <i>Journal of Clinical Virology</i> , 2016, 84, 7-11.	3.1	8
151	Maraviroc/raltegravir simplification strategy following 6 months of quadruple therapy with tenofovir/emtricitabine/maraviroc/raltegravir in treatment-naïve HIV patients. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 3235-3241.	3.2	1
152	Hepatitis E. <i>Vox Sanguinis</i> , 2016, 110, 93-103.	1.1	51
153	Transmission of HCV NS5A Inhibitor-Resistant Variants Among HIV-Infected Men Who Have Sex With Men. <i>Clinical Infectious Diseases</i> , 2016, , ciw554.	5.4	17
154	Characterization of the Specificity, Functionality, and Durability of Host Cell Responses Against the Full-Length Hepatitis E Virus. <i>Hepatology</i> , 2016, 64, 1934-1950.	10.6	47
155	ZIKA virus reveals broad tissue and cell tropism during the first trimester of pregnancy. <i>Scientific Reports</i> , 2016, 6, .	3.5	177
156	A nationwide survey of hepatitis E viral infection in French blood donors. <i>Hepatology</i> , 2016, 63, 1145-1154.	10.6	201
157	Viral load kinetics of Zika virus in plasma, urine and saliva in a couple returning from Martinique, French West Indies. <i>Journal of Clinical Virology</i> , 2016, 82, 1-4.	3.1	36
158	No selection of CXCR4-using variants in cell reservoirs of dual-mixed HIV-infected patients on suppressive maraviroc therapy. <i>Aids</i> , 2016, 30, 965-968.	2.5	2
159	Performance of an antigen assay for diagnosing acute hepatitis E virus genotype 3 infection. <i>Journal of Clinical Virology</i> , 2016, 79, 1-5.	3.1	50
160	Hepatitis E in Transplantation. <i>Current Infectious Disease Reports</i> , 2016, 18, .	2.7	16
161	Conventional and innate lymphocytes response at the acute phase of HEV infection in transplanted patients. <i>Journal of Infection</i> , 2016, 72, 723-730.	2.9	31
162	Mutation in the Hepatitis E Virus Polymerase and Outcome of Ribavirin Therapy. <i>Antimicrobial Agents and Chemotherapy</i> , 2016, 60, 1608-1614.	4.2	70

#	ARTICLE	IF	PR CITATIONS
163	Hepatitis E Virus-Induced Cryoglobulinemic Glomerulonephritis in a Nonimmunocompromised Person. American Journal of Kidney Diseases, 2016, 67, 660-663.	1.4	72
164	High Proportion of Asymptomatic Infections in an Outbreak of Hepatitis E Associated With a Spit-Roasted Piglet, France, 2013. Clinical Infectious Diseases, 2016, 62, 351-357.	5.4	102
165	Proposed reference sequences for hepatitis E virus subtypes. Journal of General Virology, 2016, 97, 537-542.	3.3	360
166	Position-specific automated processing of V3 env ultra-deep pyrosequencing data for predicting HIV-1 tropism. Scientific Reports, 2015, 5, .	3.5	9
167	Outcome of Hepatitis E Virus Infection in Patients With Inflammatory Arthritides Treated With Immunosuppressants. Medicine (United States), 2015, 94, e675.	1.3	56
168	An Early Viral Response Predicts the Virological Response to Ribavirin in Hepatitis E Virus Organ Transplant Patients. Transplantation, 2015, 99, 2124-2131.	1.2	63
169	Wildlife Reservoir for Hepatitis E Virus, Southwestern France. Emerging Infectious Diseases, 2015, 21, 1224-1226.	3.9	43
170	HIV-1 Tat Protein Induces Production of Proinflammatory Cytokines by Human Dendritic Cells and Monocytes/Macrophages through Engagement of TLR4-MD2-CD14 Complex and Activation of NF- κ B Pathway. PLoS ONE, 2015, 10, e0129425.	2.4	87
171	Boceprevir-Based Triple Antiviral Therapy for Chronic Hepatitis C Virus Infection in Kidney-Transplant Candidates. Journal of Transplantation, 2015, 2015, 1-5.	1.7	5
172	Four days a week or less on appropriate anti-HIV drug combinations provided long-term optimal maintenance in 94 patients: the ICCARRE project. FASEB Journal, 2015, 29, 2223-2234.	0.7	22
173	Hepatitis E virus seroprevalence in three hyperendemic areas: Nepal, Bangladesh and southwest France. Journal of Clinical Virology, 2015, 70, 39-42.	3.1	66
174	Prophylaxis versus pre-emptive treatment for prevention of cytomegalovirus infection in CMV-seropositive orthotopic liver-transplant recipients. Journal of Medical Virology, 2015, 87, 836-844.	3.8	14
175	Traitement de l'infection par le virus de l'hépatite E. Presse Medicale, 2015, 44, 339-342.	2.7	1
176	Le virus de l'hépatite E. Presse Medicale, 2015, 44, 328-332.	2.7	3
177	Virological failure of patients on maraviroc-based antiretroviral therapy. Journal of Antimicrobial Chemotherapy, 2015, 70, 1858-1864.	3.2	9
178	Identification of a duplicated V3 domain in NS5A associated with cirrhosis and hepatocellular carcinoma in HCV-1b patients. Journal of Clinical Virology, 2015, 69, 203-209.	3.1	6
179	Temporal evolution of the distribution of hepatitis E virus genotypes in Southwestern France. Infection, Genetics and Evolution, 2015, 35, 50-55.	2.4	34
180	Intra-host viral variability in children clinically infected with H1N1 (2009) pandemic influenza. Infection, Genetics and Evolution, 2015, 33, 47-54.	2.4	8

#	ARTICLE	IF	PR CITATIONS
181	Successful treatment of fibrosing cholestatic hepatitis with pegylated interferon, ribavirin and sofosbuvir after a combined kidney-liver transplantation. <i>Transplant International</i> , 2015, 28, 255-258.	2.1	22
182	High Cure Rate With 24 Weeks of Daclatasvir-Based Quadruple Therapy in Treatment-Experienced, Null-Responder Patients With HIV/Hepatitis C Virus Genotype 1/4 Coinfection: The ANRS HC30 QUADRIH Study. <i>Clinical Infectious Diseases</i> , 2015, 61, 817-825.	5.4	14
183	Performance of a new rapid test for detecting anti-hepatitis E virus immunoglobulin M in immunocompetent and immunocompromised patients. <i>Journal of Clinical Virology</i> , 2015, 70, 101-104.	3.1	23
184	Protracted Fecal Shedding of HEV During Ribavirin Therapy Predicts Treatment Relapse. <i>Clinical Infectious Diseases</i> , 2015, 60, 96-99.	5.4	69
185	Hepatitis E virus: Chronic infection, extra-hepatic manifestations, and treatment. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2015, 39, 20-27.	1.9	90
186	Variability and pathogenicity of hepatitis E virus genotype 3 variants. <i>Journal of General Virology</i> , 2015, 96, 3255-3264.	3.3	55
187	An Association between BK Virus Replication in Bone Marrow and Cytopenia in Kidney-Transplant Recipients. <i>Journal of Transplantation</i> , 2014, 2014, 1-9.	1.7	7
188	Virological Diagnosis of Central Nervous System Infections by Use of PCR Coupled with Mass Spectrometry Analysis of Cerebrospinal Fluid Samples. <i>Journal of Clinical Microbiology</i> , 2014, 52, 212-217.	4.1	22
189	Influence of Polyproline Region and Macro Domain Genetic Heterogeneity on HEV Persistence in Immunocompromised Patients. <i>Journal of Infectious Diseases</i> , 2014, 209, 300-303.	3.8	59
190	Chikungunya in the Caribbean—Threat for Europe. <i>Emerging Infectious Diseases</i> , 2014, 20, .	3.9	9
191	Hepatitis E Virus Infections in Blood Donors, France. <i>Emerging Infectious Diseases</i> , 2014, 20, 1914-1917.	3.9	128
192	Evolution of HIV-1 quasispecies and coreceptor use in cell reservoirs of patients on suppressive antiretroviral therapy. <i>Journal of Antimicrobial Chemotherapy</i> , 2014, 69, 2527-2530.	3.2	18
193	Hepatitis E in Developed Countries: Current Status and Future Perspectives. <i>Future Microbiology</i> , 2014, 9, 1361-1372.	2.1	55
194	HIV-1 Tat Protein Induces PD-L1 (B7-H1) Expression on Dendritic Cells through Tumor Necrosis Factor Alpha- and Toll-Like Receptor 4-Mediated Mechanisms. <i>Journal of Virology</i> , 2014, 88, 6672-6689.	3.7	53
195	Ribavirin for Chronic Hepatitis E Virus Infection in Transplant Recipients. <i>New England Journal of Medicine</i> , 2014, 370, 1111-1120.	43.7	482
196	Hepatitis E Virus Infection. <i>Clinical Microbiology Reviews</i> , 2014, 27, 116-138.	17.4	574
197	Safety measures to prevent hepatitis E virus transmission by blood transfusion. <i>Transfusion</i> , 2014, 54, 2134-2135.	0.8	4
198	Characterization of the Polyproline Region of the Hepatitis E Virus in Immunocompromised Patients. <i>Journal of Virology</i> , 2014, 88, 12017-12025.	3.7	65

#	ARTICLE	IF	PR CITATIONS
199	Hepatitis E Virus Reinfections in Solid-Organ-Transplant Recipients Can Evolve Into Chronic Infections. <i>Journal of Infectious Diseases</i> , 2014, 209, 1900-1906.	3.8	154
200	An international multicenter study on HIV-1 drug resistance testing by 454 ultra-deep pyrosequencing. <i>Journal of Virological Methods</i> , 2014, 204, 31-37.	1.7	31
201	Apolipoprotein H expression is associated with IL28B genotype and viral clearance in hepatitis C virus infection. <i>Journal of Hepatology</i> , 2014, 61, 770-776.	3.6	10
202	Chronic Hepatitis E Virus Infection and Treatment. <i>Journal of Clinical and Experimental Hepatology</i> , 2013, 3, 134-140.	2.5	69
203	Performance of anti-HEV assays for diagnosing acute hepatitis E in immunocompromised patients. <i>Journal of Clinical Virology</i> , 2013, 58, 624-628.	3.1	114
204	Risk of zoonotic transmission of HEV from rabbits. <i>Journal of Clinical Virology</i> , 2013, 58, 357-362.	3.1	60
205	Primary resistance of CCR5-tropic HIV-1 to maraviroc cannot be predicted by the V3 sequence. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2506-2514.	3.2	10
206	Evaluation of a polymerase chain reaction-electrospray ionization time-of-flight mass spectrometry for the detection and subtyping of influenza viruses in respiratory specimens. <i>Journal of Clinical Virology</i> , 2013, 57, 222-226.	3.1	17
207	Hepatitis C virus and kidney disease. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2013, 37, 328-333.	1.9	17
208	Hepatitis E virus infection. <i>Current Opinion in Gastroenterology</i> , 2013, 29, 271-278.	2.3	37
209	Characterization of CXCR4-using HIV-1 during primary infection by ultra-deep pyrosequencing. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2875-2881.	3.2	13
210	Genotypic Prediction of HIV-1 CRF01-AE Tropism. <i>Journal of Clinical Microbiology</i> , 2013, 51, 564-570.	4.1	34
211	National sentinel surveillance of transmitted drug resistance in antiretroviral-naïve chronically HIV-infected patients in France over a decade: 2001-2011. <i>Journal of Antimicrobial Chemotherapy</i> , 2013, 68, 2626-2631.	3.2	43
212	Hepatitis E Virus Infection in Immunosuppressed Patients: Natural History and Therapy. <i>Seminars in Liver Disease</i> , 2013, 33, 062-070.	3.4	90
213	An Analysis of the Benefit of Using HEV Genotype 3 Antigens in Detecting Anti-HEV IgG in a European Population. <i>PLoS ONE</i> , 2013, 8, e62980.	2.4	56
214	Hepatitis E Virus Quasispecies and the Outcome of Acute Hepatitis E in Solid-Organ Transplant Patients. <i>Journal of Virology</i> , 2012, 86, 10006-10014.	3.7	102
215	Phenotyping methods for determining HIV tropism and applications in clinical settings. <i>Current Opinion in HIV and AIDS</i> , 2012, 7, 463-469.	3.3	18
216	Presence of Lamivudine or Emtricitabine Is Associated with Reduced Emergence of Nonnucleoside Reverse Transcriptase Inhibitor Mutations in an Efavirenz-Based Intermittent Antiretroviral Treatment Regimen. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 1655-1657.	4.2	9

#	ARTICLE	IF	PR CITATIONS
217	Genotype 3 Diversity and Quantification of Hepatitis E Virus RNA. <i>Journal of Clinical Microbiology</i> , 2012, 50, 897-902.	4.1	118
218	Hepatitis E Virus and the Kidney in Solid-Organ Transplant Patients. <i>Transplantation</i> , 2012, 93, 617-623.	1.2	186
219	Antiviral Effect of Maraviroc in Semen: A Case Report. <i>Antiviral Therapy</i> , 2012, 17, 933-936.	2.1	8
220	Hepatitis E. <i>Lancet</i> , The, 2012, 379, 2477-2488.	52.8	899
221	Performance of a rapid molecular multiplex assay for the detection of influenza and picornaviruses. <i>Scandinavian Journal of Infectious Diseases</i> , 2012, 44, 963-968.	1.6	9
222	Low risk of hepatitis E virus reactivation after haematopoietic stem cell transplantation. <i>Journal of Clinical Virology</i> , 2012, 54, 152-155.	3.1	58
223	HIV-1 Tropism and Liver Fibrosis in HIV/HCV Co-Infected Patients. <i>PLoS ONE</i> , 2012, 7, e50289.	2.4	5
224	Hepatitis E Virus Strains in Rabbits and Evidence of a Closely Related Strain in Humans, France. <i>Emerging Infectious Diseases</i> , 2012, 18, .	3.9	243
225	Factors Associated With Chronic Hepatitis in Patients With Hepatitis E Virus Infection Who Have Received Solid Organ Transplants. <i>Gastroenterology</i> , 2011, 140, 1481-1489.	1.0	624
226	X4 Tropic Multi-Drug Resistant Quasi-Species Detected at the Time of Primary HIV-1 Infection Remain Exclusive or at Least Dominant Far from PHI. <i>PLoS ONE</i> , 2011, 6, e23301.	2.4	6
227	Genotypic prediction of HIV-1 subtype D tropism. <i>Retrovirology</i> , 2011, 8, .	3.6	40
228	Hepatitis E Virus Infection without Reactivation in Solid-Organ Transplant Recipients, France. <i>Emerging Infectious Diseases</i> , 2011, 17, 30-37.	3.9	143
229	Hepatitis E Virus and Neurologic Disorders. <i>Emerging Infectious Diseases</i> , 2011, 17, 173-179.	3.9	304
230	Hepatitis E Virus Antibodies in Blood Donors, France. <i>Emerging Infectious Diseases</i> , 2011, 17, 2309-2312.	3.9	325
231	Improved V3 genotyping with duplicate PCR amplification for determining HIV-1 tropism. <i>Journal of Antimicrobial Chemotherapy</i> , 2011, 66, 1972-1975.	3.2	14
232	Concordance between Two Phenotypic Assays and Ultradeep Pyrosequencing for Determining HIV-1 Tropism. <i>Antimicrobial Agents and Chemotherapy</i> , 2011, 55, 2831-2836.	4.2	46
233	Frequency of CXCR4-using viruses in primary HIV-1 infections using ultra-deep pyrosequencing. <i>Aids</i> , 2011, 25, 1668-1670.	2.5	24
234	Definitive Clearance of a Chronic Hepatitis E Virus Infection With Ribavirin Treatment. <i>American Journal of Gastroenterology</i> , 2011, 106, 1562-1563.	0.7	46

#	ARTICLE	IF	PR CITATIONS
235	Decreased prevalence and incidence of HCV markers in haemodialysis units: a multicentric French survey. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 2309-2316.	0.8	54
236	Minor HIV-1 Variants with the K103N Resistance Mutation during Intermittent Efavirenz-Containing Antiretroviral Therapy and Virological Failure. <i>PLoS ONE</i> , 2011, 6, e21655.	2.4	35
237	Hepatitis E Virus Seroprevalence and Chronic Infections in Patients with HIV, Switzerland. <i>Emerging Infectious Diseases</i> , 2011, 17, 1074-1078.	3.9	130
238	No evidence of occult hepatitis C virus (HCV) infection in serum of HCV antibody-positive HCV RNA-negative kidney-transplant patients. <i>Transplant International</i> , 2010, 23, 594-601.	2.1	55
239	Prediction of HIV Type 1 Subtype C Tropism by Genotypic Algorithms Built From Subtype B Viruses. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2010, 53, 167-175.	1.8	52
240	Influence of Immunosuppressive Therapy on the Natural History of Genotype 3 Hepatitis-E Virus Infection After Organ Transplantation. <i>Transplantation</i> , 2010, 89, 353-360.	1.2	215
241	Characteristics of Autochthonous Hepatitis E Virus Infection in Solidâ€œOrgan Transplant Recipients in France. <i>Journal of Infectious Diseases</i> , 2010, 202, 835-844.	3.8	179
242	Hepatitis E virus infection as a cause of graft hepatitis in liver transplant recipients. <i>Liver Transplantation</i> , 2010, 16, 74-82.	2.6	184
243	Low Frequency of CXCR4-Using Viruses in Patients at the Time of Primary Non-Subtype-B HIV-1 Infection. <i>Journal of Clinical Microbiology</i> , 2010, 48, 3487-3491.	4.1	26
244	Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial. <i>Journal of Antimicrobial Chemotherapy</i> , 2010, 65, 2436-2444.	3.2	47
245	Pegylated Interferonâ€œ± for Treating Chronic Hepatitis E Virus Infection after Liver Transplantation. <i>Clinical Infectious Diseases</i> , 2010, 50, e30-e33.	5.4	197
246	Evaluation of the Genotypic Prediction of HIV-1 Coreceptor Use versus a Phenotypic Assay and Correlation with the Virological Response to Maraviroc: the ANRS GenoTropism Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2010, 54, 3335-3340.	4.2	65
247	Three-month pegylated interferon-alpha-2a therapy for chronic hepatitis E virus infection in a haemodialysis patient. <i>Nephrology Dialysis Transplantation</i> , 2010, 25, 2792-2795.	0.8	100
248	Influence of pre-analytical conditions on plasma ribavirin concentrations. <i>Arzneimittelforschung</i> , 2010, 60, 636-639.	0.8	2
249	Ribavirin Therapy Inhibits Viral Replication on Patients With Chronic Hepatitis E Virus Infection. <i>Gastroenterology</i> , 2010, 139, 1612-1618.	1.0	279
250	Development and performance of a new recombinant virus phenotypic entry assay to determine HIV-1 coreceptor usage. <i>Journal of Clinical Virology</i> , 2010, 47, 126-130.	3.1	66
251	Hepatitis E virus excretion can be prolonged in patients with hematological malignancies. <i>Journal of Clinical Virology</i> , 2010, 49, 141-144.	3.1	127
252	Hepatitis C Virus Genotyping Using an Oligonucleotide Microarray Based on the NS5B Sequence. <i>Journal of Clinical Microbiology</i> , 2010, 48, 3910-3917.	4.1	21

#	ARTICLE	IF	PR CITATIONS
253	CXCR4-using viruses in plasma and peripheral blood mononuclear cells during primary HIV-1 infection and impact on disease progression. <i>Aids</i> , 2010, 24, 2305-2312.	2.5	76
254	HIV-1 Residual Viremia Correlates with Persistent T-Cell Activation in Poor Immunological Responders to Combination Antiretroviral Therapy. <i>PLoS ONE</i> , 2009, 4, e7658.	2.4	120
255	Determining Seminal Plasma Human Immunodeficiency Virus Type 1 Load in the Context of Efficient Highly Active Antiretroviral Therapy. <i>Journal of Clinical Microbiology</i> , 2009, 47, 2883-2887.	4.1	28
256	Good Performance of Immunoglobulin M Assays in Diagnosing Genotype 3 Hepatitis E Virus Infections. <i>Vaccine Journal</i> , 2009, 16, 772-774.	3.0	84
257	Genotypic Prediction of Human Immunodeficiency Virus Type 1 CRF02-AG Tropism. <i>Journal of Clinical Microbiology</i> , 2009, 47, 2292-2294.	4.1	48
258	Hepatitis E Virus Genotype 3 Diversity, France. <i>Emerging Infectious Diseases</i> , 2009, 15, 110-114.	3.9	144
259	Molecular Evidence of Patient-to-Patient Transmission of Hepatitis E Virus in a Hematology Ward. <i>Clinical Infectious Diseases</i> , 2009, 48, 373-374.	5.4	51
260	Influence of the HCV subtype on the virological response to pegylated interferon and ribavirin therapy. <i>Journal of Medical Virology</i> , 2009, 81, 2029-2035.	3.8	56
261	Mathematical modeling of hepatitis C virus transmission in hemodialysis. <i>American Journal of Infection Control</i> , 2009, 37, 403-407.	2.1	15
262	High prevalence of anti-hepatitis E virus antibodies in blood donors from South West France. <i>Journal of Medical Virology</i> , 2008, 80, 289-293.	3.8	166
263	Serum concentrations of ribavirin and pegylated interferon and viral responses in patients infected with HIV and HCV. <i>Journal of Medical Virology</i> , 2008, 80, 1523-1529.	3.8	37
264	Hepatitis E Virus and Chronic Hepatitis in Organ-Transplant Recipients. <i>New England Journal of Medicine</i> , 2008, 358, 811-817.	43.7	1,296
265	Correlation between genotypic predictions based on V3 sequences and phenotypic determination of HIV-1 tropism. <i>Aids</i> , 2008, 22, F11-F16.	2.5	115
266	Population-Based Sequencing of the V3 Region of <i>env</i> for Predicting the Coreceptor Usage of Human Immunodeficiency Virus Type 1 Quasispecies. <i>Journal of Clinical Microbiology</i> , 2007, 45, 1572-1580.	4.1	86
267	New Natural Intergenotypic (2/5) Recombinant of Hepatitis C Virus. <i>Journal of Virology</i> , 2007, 81, 4357-4362.	3.7	105
268	Genetic diversity of HCV genotype 2 strains in South Western France. <i>Journal of Medical Virology</i> , 2007, 79, 26-34.	3.8	24
269	Determining the source of nosocomial transmission in hemodialysis units in Tunisia by sequencing NS5B and E2 sequences of HCV. <i>Journal of Medical Virology</i> , 2007, 79, 1089-1094.	3.8	17
270	Prolonged hepatitis E in an immunocompromised patient. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2006, 21, 1223-1224.	2.7	76

#	ARTICLE	IF	PR CITATIONS
271	Hepatitis E is an autochthonous disease in industrialized countries. <i>Gastroenterologie Clinique Et Biologique</i> , 2006, 30, 757-762.	1.0	65
272	Validation of an automated real-time PCR protocol for detection and quantitation of HIV and HCV genomes in semen. <i>Journal of Virological Methods</i> , 2006, 137, 156-159.	1.7	16
273	Repeated HIV-1 resistance genotyping external quality assessments improve virology laboratory performance. <i>Journal of Medical Virology</i> , 2006, 78, 153-160.	3.8	56
274	Twenty-four hour kinetics of hepatitis C virus and antiviral effect of alpha-interferon. <i>Journal of Medical Virology</i> , 2006, 78, 365-371.	3.8	14
275	Acute hepatitis and renal function impairment related to infection by hepatitis E virus in a renal allograft recipient. <i>American Journal of Kidney Diseases</i> , 2005, 45, 193-196.	1.4	58
276	Natural History of Hepatitis C Virus-Related Liver Fibrosis After Renal Transplantation. <i>American Journal of Transplantation</i> , 2005, 5, 1704-1712.	4.6	119
277	Factors accelerating liver fibrosis progression in renal transplant patients receiving ribavirin monotherapy for chronic hepatitis C. <i>Journal of Medical Virology</i> , 2005, 76, 61-68.	3.8	28
278	Pegylated interferon and ribavirin therapy for chronic hepatitis C virus genotype 4 infection. <i>Journal of Medical Virology</i> , 2005, 77, 66-69.	3.8	50
279	Incidence of HCV infection in French hemodialysis units: A prospective study. <i>Journal of Medical Virology</i> , 2005, 77, 70-76.	3.8	75
280	R5 to X4 Switch of the Predominant HIV-1 Population in Cellular Reservoirs During Effective Highly Active Antiretroviral Therapy. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2005, 38, 382-392.	1.8	107
281	Convenient Biological Assay for Polyethylene Glycol-Interferons in Patients with Hepatitis C. <i>Antimicrobial Agents and Chemotherapy</i> , 2004, 48, 3610-3612.	4.2	6
282	Immunologically Silent Autochthonous Acute Hepatitis E Virus Infection in France. <i>Journal of Clinical Microbiology</i> , 2004, 42, 912-913.	4.1	47
283	Factors of intermittent HIV-1 excretion in semen and efficiency of sperm processing in obtaining spermatozoa without HIV-1 genomes. <i>Aids</i> , 2004, 18, 757-766.	2.5	80
284	Ribavirin pharmacokinetics in renal and liver transplant patients: evidence that it depends on renal function. <i>American Journal of Kidney Diseases</i> , 2004, 43, 140-146.	1.4	77
285	Hepatitis E in the south west of France in individuals who have never visited an endemic area. <i>Journal of Medical Virology</i> , 2004, 74, 419-424.	3.8	233
286	Evidence that Clearance of Hepatitis C Virus RNA after Î±-Interferon Therapy in Dialysis Patients Is Sustained after Renal Transplantation. <i>Journal of the American Society of Nephrology: JASN</i> , 2003, 14, 2092-2098.	0.4	174
287	Genetic Heterogeneity of the NS5A Gene of Hepatitis C Virus and Early Response to Interferon. <i>Journal of Infectious Diseases</i> , 2003, 188, 1367-1370.	3.8	9
288	Evolution of Total and Integrated HIV-1 DNA and Change in DNA Sequences in Patients with Sustained Plasma Virus Suppression. <i>Virology</i> , 2002, 302, 393-404.	2.3	30

#	ARTICLE	IF	PR CITATIONS
289	Low-Rate Emergence of Thymidine Analogue Mutations and Multi-Drug Resistance Mutations in the HIV-1 Reverse Transcriptase Gene in Therapy-Naive Patients Receiving Stavudine plus Lamivudine Combination Therapy. <i>Antiviral Therapy</i> , 2001, 6, 179-183.	2.1	27
290	Hepatitis C virus infection in French hemodialysis units: A multicenter study. <i>Journal of Medical Virology</i> , 2000, 61, 44-51.	3.8	73
291	A pharmacokinetic model for alpha interferon administered subcutaneously. <i>British Journal of Clinical Pharmacology</i> , 1999, 47, 365-371.	2.7	47
292	Molecular evidence for nosocomial transmission of hepatitis C virus in a French hemodialysis unit. <i>Journal of Medical Virology</i> , 1999, 58, 139-144.	3.8	85
293	TREATMENT OF CHRONIC HEPATITIS C WITH RECOMBINANT INTERFERON ALPHA IN KIDNEY TRANSPLANT RECIPIENTS. <i>Transplantation</i> , 1995, 59, 1426-1431.	1.2	189